About this trial
This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of topical 10% high-concentration 35 kDa hyaluronan (HA35) gel for ultra-rapid relief of moderate-to-severe skin pruritus from diverse etiologies (eczema, neurodermatitis, insect bites, urticaria, postoperative wound itch). Eligible participants will receive a single topical application of HA35 gel. The primary objective is to assess pruritus relief at 10 seconds, 45 minutes, 8 hours, 12 hours, and 24 hours post-application. Safety and local skin tolerability will be evaluated throughout the observation period. This is a minimal-risk, non-pharmacological, non-invasive intervention.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age 18-65 years, male or female
Moderate-to-severe skin pruritus (NRS ≥6) due to eczema, neurodermatitis, insect bites, urticaria, or postoperative wound itch
Able to understand and complete NRS assessments independently
Signed written informed consent
Disqualifiers
Topical corticosteroid/antihistamine use within 2 weeks
Infected, broken, or exudative skin lesions at the application site
Known hypersensitivity to hyaluronan or gel components
Severe systemic disease or immune dysfunction
Trial design
Single group
Treatments tested in this trial
10% High-Concentration 35 kDa Hyaluronan (HA35) Topical Anti-Pruritic Gel
DeviceTopical skin gel containing 10% high-concentration 35 kDa hyaluronan fragment. Applied topically to pruritic areas to provide ultra-rapid relief of skin itching and improve associated inflammatory signs.
Treatment groups
Trial outcomes
Primary outcomes
Change in Skin Pruritus NRS Score (0-10)
Change in pruritus intensity measured by 0-10 NRS, 0 = no itching, 10 = worst imaginable itching.
Secondary outcomes
Onset time of clinically significant pruritus relief
Duration of pruritus relief
Change in Skin Erythema Severity (0-10 NRS Score)
Change in skin erythema severity at the application site, assessed using a 0-10 Numeric Rating Scale (NRS), where 0 = no erythema and 10 = maximum redness.
Change in Local Skin Swelling Severity (0-10 NRS Score)
Change in local skin swelling severity at the application site, assessed using a 0-10 Numeric Rating Scale (NRS), where 0 = no swelling and 10 = maximum swelling.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: